Q-omics provides the consensus-scored PARN profile across patient tissues and cancer cell-line models. PARN expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PARN is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, PARN protein abundance shows 37,973 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, and GBM as cancer lineages where PARN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PARN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PARN survival associations across molecular data types. PARN RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PARN RNA expression–survival associations across cancer types. High PARN expression shows unfavorable associations in HNSC, PAAD, BLCA, LGG, STAD and ACC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for PARN RNA expression.
This table summarizes PARN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 12. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PARN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PARN shows higher tumor expression in HNSC, KIRC, KIRP, LIHC, COAD and LUAD. The HNSC box plot shows higher PARN RNA expression in tumor versus normal tissue (log2 FC = +1.215, t-test p < 0.001).
This table shows molecular features associated with PARN in patient tissues and cancer cell lines. In patient samples, PARN shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PARN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and UPPER_AERODIGESTIVE_TRACT.
